IXICO Awarded Phase III Liver Cancer Study

Share Article

IXICO, Ltd., a global imaging CRO, announced today that a leading academic institution has awarded IXICO a Phase III clinical imaging study. IXICO will provide clinical study management and full imaging services. The study will assess the efficacy of a proprietary drug in combination with transcatheter arterial chemoembolization (TACE) in the treatment of unresectable hepatocellular carcinoma (HCC) using the response evaluation criteria in solid tumours (RECIST). RECIST is the accepted standard for measuring tumor response to therapeutic intervention, using X-ray, CT, or MR images.

Our solution combines the latest release of our image management technology with rigorous application of well established radiological endpoints to provide the study flexibility that the investigators require

IXICO, Ltd., a global imaging CRO, announced today that a leading academic institution has awarded IXICO a Phase III clinical imaging study. IXICO will provide clinical study management and full imaging services. The study will assess the efficacy of a proprietary drug in combination with transcatheter arterial chemoembolization (TACE) in the treatment of unresectable hepatocellular carcinoma (HCC) using the response evaluation criteria in solid tumours (RECIST). RECIST is the accepted standard for measuring tumor response to therapeutic intervention, using X-ray, CT, or MR images.

The study will commence in spring 2010, recruiting more than 400 patients at dozens of sites, over a three year period. IXICO will provide protocol consultation, site management (site evaluation, qualification, training and communications), image handling (data transfer and storage via IXICO's TrialTrackerâ„¢ Image Management System), real-time image data QC, reporting, and analysis of CT and MR images using RECIST. The award of this liver cancer study demonstrates IXICO's growing backlog of RECIST studies based on our core therapeutic area strengths specifically in oncology and neurodegeneration.

"The award of this Phase III, oncology study demonstrates that our customers recognize the value of IXICO's innovative imaging solutions, which provide higher image quality and shorter timelines" notes Derek Hill, CEO. "Our solution combines the latest release of our image management technology with rigorous application of well established radiological endpoints to provide the study flexibility that the investigators require".

About IXICO
IXICO, Ltd. is a full-service Imaging CRO that provides comprehensive, technology-based solutions for the pharmaceutical and biotech industries across all therapeutic areas and clinical trials phases. IXICO works within an ISO9001:2008 certified Quality Management System.

For more information please contact: Erin Coberth, Contracts & Proposals Manager at erin (dot) coberth (at) ixico (dot) com
IXICO, Ltd. The London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH England - http://www.ixico.com

© 2010 IXICO, Ltd. All rights reserved

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Marketing IXICO
Visit website